Skip to main content
. 2019 Jun 17;4(3):e000498. doi: 10.1136/esmoopen-2019-000498

Table 2.

Immune checkpoint inhibitor efficacy outcomes in various molecular alterations

Driver n Best response (%) PFS OS
CR/PR SD PD Median (months) 6 month PFS (%) 1 year PFS (%) Median (months)
BRAF 38 28.1 28.1 43.8 3 35 19 13.6
KRAS 252 27.2 23.1 49.8 3.2 39 26 13.5
ROS1 5 20 0 80 NA NA NA NA
MET 36 15.6 34.4 50 3.4 33 23 18.4
EGFR 110 11 18 71 2 16 6 8.8
HER2 23 9.5 28.6 61.9 3.5 34 17 10
RET 14 7.1 21.4 71.4 2.2 16 8 6.5
ALK 18 0 21.4 78.6 2.1 16 8 17

Reprinted with permission from American Society of Clinical Oncology. Copyright 2018. All rights reserved. Mazieres J, Drilon AE, Mhanna LJ et al. Efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients harbouring activating molecular alterations (ImmunoTarget). J Clin Oncol 2018; 36, suppl:abstr 9010.

CR, complete response; NA, not available; PFS, progression-free survival; PR, partial response.